{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000030","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.549703+00:00","generated_at":"2026-05-18T02:23:17.308577+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3","bullets":["Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.","4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.","Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.","PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.","Cash and investments $911.5M as of June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000030","json":"https://secwatch.observer/filing/0001645113-25-000030.json","markdown":"https://secwatch.observer/filing/0001645113-25-000030.md","text":"https://secwatch.observer/filing/0001645113-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/0001645113-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/nvcr-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T02:23:17.308577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}